Pancreatic Cancer Research

ResearcherHarvard UniversityNo recent work listed

Janet E. Murphy

Verified by OpenAlex author ID (good confidence, 0.85), identity_conf@1As of 7 November 2026

Matched on OpenAlex author ID A5063179737. Sources: OpenAlex.

Their work

Papers
11 (first author 1, last author 0)
Trials
0
Grants
0
Labs led
0
Collaborators
50
Papers, trials and grants by year

2013: 1 paper · 2014: none · 2015: 1 paper · 2016: none · 2017: 2 papers · 2018: 3 papers · 2019: 2 papers · 2020: none · 2021: none · 2022: 1 paper · 2023: 1 paper

Papers 11

  1. Effect of a MUC5AC Antibody (NPC-1C) Administered With Second-Line Gemcitabine and Nab-Paclitaxel on the Survival of Patients With Advanced Pancreatic Ductal A… Co-author DOI 10.1001/jamanetworkopen.2022.49720↗
  2. Prospective Phase II Trials Validate the Effect of Neoadjuvant Chemotherapy on Pattern of Recurrence in Pancreatic Adenocarcinoma. Co-author DOI 10.1097/sla.0000000000004585↗
  3. Total Neoadjuvant Therapy With FOLFIRINOX in Combination With Losartan Followed by Chemoradiotherapy for Locally Advanced Pancreatic Cancer: A Phase 2 Clinical… Co-author DOI 10.1001/jamaoncol.2019.0892↗
  4. Predictors of Resectability and Survival in Patients With Borderline and Locally Advanced Pancreatic Cancer who Underwent Neoadjuvant Treatment With FOLFIRINOX. Co-author DOI 10.1097/sla.0000000000002600↗
  5. Total Neoadjuvant Therapy With FOLFIRINOX Followed by Individualized Chemoradiotherapy for Borderline Resectable Pancreatic Adenocarcinoma: A Phase 2 Clinical … Co-author DOI 10.1001/jamaoncol.2018.0329↗
  6. Tolerability and Long-term Outcomes of Dose-Painted Neoadjuvant Chemoradiation to Regions of Vessel Involvement in Borderline or Locally Advanced Pancreatic Ca… Co-author DOI 10.1097/coc.0000000000000349↗
  7. Real-time Genomic Characterization of Advanced Pancreatic Cancer to Enable Precision Medicine. Co-author DOI 10.1158/2159-8290.cd-18-0275↗
  8. Post-Whipple imaging in patients with pancreatic ductal adenocarcinoma: association with overall survival: a multivariate analysis. First author DOI 10.1007/s00261-017-1099-2↗
  9. Use of Angiotensin System Inhibitors Is Associated with Immune Activation and Longer Survival in Nonmetastatic Pancreatic Ductal Adenocarcinoma. Co-author DOI 10.1158/1078-0432.ccr-17-0256↗
  10. Radiological and surgical implications of neoadjuvant treatment with FOLFIRINOX for locally advanced and borderline resectable pancreatic cancer. Co-author DOI 10.1097/sla.0000000000000867↗
  11. FOLFIRINOX in locally advanced pancreatic cancer: the Massachusetts General Hospital Cancer Center experience. Co-author DOI 10.1634/theoncologist.2012-0435↗

Closest collaborators

The 25 strongest of 50 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Theodore Sunki Hong · 8 shared papers, 2013–2022 · strength 0.51
  2. David P. Ryan · 8 shared papers, 2013–2022 · strength 0.51
  3. Cristina Rosa Ferrone · 8 shared papers, 2013–2022 · strength 0.51
  4. Keith D. Lillemoe · 8 shared papers, 2013–2022 · strength 0.51
  5. Jennifer Yon-Li Wo · 7 shared papers, 2013–2022 · strength 0.46
  6. Carlos F. Fernandez-del Castillo · 6 shared papers, 2015–2022 · strength 0.44
  7. Lawrence Scott Blaszkowsky · 6 shared papers, 2013–2019 · strength 0.33
  8. Vikram Deshpande · 4 shared papers, 2015–2022 · strength 0.29
  9. Motaz Qadan · 3 shared papers, 2019–2022 · strength 0.27
  10. Aparna R. Parikh · 3 shared papers, 2019–2022 · strength 0.27
  11. Jason Edward Faris · 5 shared papers, 2013–2019 · strength 0.26
  12. Eunice Lee Kwak · 5 shared papers, 2013–2019 · strength 0.26
  13. David Tsai Ting · 3 shared papers, 2015–2022 · strength 0.23
  14. Ryan David Nipp · 3 shared papers, 2018–2019 · strength 0.20
  15. Colin D. Weekes · 2 shared papers, 2019–2022 · strength 0.19
  16. Hanna Kelly Sanoff · 1 shared paper, 2023 · strength 0.15
  17. Muhammad Shaalan Beg · 1 shared paper, 2023 · strength 0.15
  18. Atrayee Basu Mallick · 1 shared paper, 2023 · strength 0.15
  19. Peter J. Hosein · 1 shared paper, 2023 · strength 0.15
  20. Michael Andrew Morse · 1 shared paper, 2023 · strength 0.15
  21. Brian Matthew Wolpin · 1 shared paper, 2023 · strength 0.15
  22. Brandon M. Huffman · 1 shared paper, 2023 · strength 0.15
  23. Jill Lacy · 1 shared paper, 2023 · strength 0.15
  24. Andrea Wang‐Gillam · 1 shared paper, 2023 · strength 0.15
  25. James M. Cleary · 1 shared paper, 2023 · strength 0.15

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.